Withaferin A targets apoptosis inhibitor cIAP1: A potential anticancer candidate

Wadegaonkar, V. P.; Wadegaonkar, P. A.
May 2012
Journal of Applied Pharmaceutical Science;May2012, Vol. 2 Issue 5, p1
Academic Journal
Inhibitors of Apoptosis (IAPs) are important and well studied molecules in the cancer pathway. These are known inhibitors of apoptosis and are over expressed in many tumours where they confer chemo-resistance. The cIAP1 inhibits caspase 3 and caspase 7 and ensures suppression of apoptosis. Docking studies carried out with herbal ligand withaferin A derived from roots of Withania somnifera onto the structure of cIAP1. Withaferin A has shown strong binding affinity of -15.4988 kJ/mol with BIR domain of cIAP1 and in turn interfere in the binding of cIAP1 molecule to caspase 3 and caspase 7 and thus result into prevention of inhibition of these effecter proteins. The docking studies support the experimental outcomes and suggest that withaferin A has potential to develop as candidate molecule for cancer therapy.


Related Articles

  • Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target? Breimer, Lars H.; Mikhailidis, Dimitri P. // Current Pharmaceutical Design;11/11/2011, Vol. 17 Issue 33, p3644 

    Normal aerobic metabolism is associated with reactive oxygen species (ROS) that can damage cellular macromolecules. Analogous free radicals are formed by exposure to ionizing radiation and many dietary products are considered to contain free radical generators. During the past 15 years...

  • Cellular Protection and Therapeutic Potential of Tocotrienols. Catalgol, Betul; Batirel, Saime; Ozer, Nesrin Kartal // Current Pharmaceutical Design;7/11/2011, Vol. 17 Issue 21, p2215 

    Tocotrienols, components belonging to vitamin E members, are used as potent therapeutics in the treatment of several diseases. Recent studies suggested tocotrienol to have better activity in many situations compared to tocopherols. Tocotrienols have been shown to lower the atherogenic...

  • Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Lovly, Christine M; McDonald, Nerina T; Chen, Heidi; Ortiz-Cuaran, Sandra; Heukamp, Lukas C; Yan, Yingjun; Florin, Alexandra; Ozretić, Luka; Lim, Diana; Wang, Lu; Chen, Zhao; Chen, Xi; Lu, Pengcheng; Paik, Paul K; Shen, Ronglai; Jin, Hailing; Buettner, Reinhard; Ansén, Sascha; Perner, Sven; Brockmann, Michael // Nature Medicine;Sep2014, Vol. 20 Issue 9, p1027 

    Crizotinib, a selective tyrosine kinase inhibitor (TKI), shows marked activity in patients whose lung cancers harbor fusions in the gene encoding anaplastic lymphoma receptor tyrosine kinase (ALK), but its efficacy is limited by variable primary responses and acquired resistance. In work arising...

  • O3–049SYNERGISTIC INTERACTION BETWEEM OLAPARIB, A PARP INHIBITOR, AND CYTOTOXIC AGENT IN TRIPLE NEGATIVE BREAST CANCER. Hashimoto, J.; Kitamura, Y.; Takashima, Y.; Kodera, Y.; Shimma, S.; Hamada, A.; Fujiwara, Y.; Koizumi, F.; Tamura, K. // Annals of Oncology;Nov2013 Supplement 9, Vol. 24, pix59 

    No abstract available.

  • Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy. de Virgilio, Maddalena; Silvestris, Franco // Current Pharmaceutical Design;6/30/2011, Vol. 17 Issue 19, p1979 

    The urokinase receptor (uPAR) exerts essential functions in the pathophysiology of cancers and therefore constitutes an important drug target. In order to generate efficient drugs against uPAR, a new approach includes chimeric proteins associating one molecular address to specifically target...

  • Potential New Anticancer Molecular Targets for the Treatment of Human Testicular Seminomas. Chieffi, P. // Mini Reviews in Medicinal Chemistry;Oct2011, Vol. 11 Issue 12, p1075 

    In the last years novel therapeutic approaches for the treatment of cancer have been proposed: specific inhibitors of serine/threonine and tyrosine kinases, angiogenesis inhibitors, antibodies against receptors/surface molecules on cancer cells, gene therapy approaches and others. In a lot of...

  • Structure-Based Development of Small Molecule PFKFB3 Inhibitors: A Framework for Potential Cancer Therapeutic Agents Targeting the Warburg Effect. Seo, Minsuh; Kim, Jeong-Do; Neau, David; Sehgal, Inder; Lee, Yong-Hwan // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    Cancer cells adopt glycolysis as the major source of metabolic energy production for fast cell growth. The HIF-1-induced PFKFB3 plays a key role in this adaptation by elevating the concentration of Fru-2,6-BP, the most potent glycolysis stimulator. As this metabolic conversion has been suggested...

  • Mitochondria Are the Target Organelle of Differentiation-Inducing Factor-3, an Anti-Tumor Agent Isolated from Dictyostelium Discoideum. Kubohara, Yuzuru; Kikuchi, Haruhisa; Matsuo, Yusuke; Oshima, Yoshiteru; Homma, Yoshimi // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Differentiation-inducing factor-3 (DIF-3), found in the cellular slime mold Dictyostelium discoideum, and its derivatives such as butoxy-DIF-3 (Bu-DIF-3) are potent anti-tumor agents. However, the precise mechanisms underlying the actions of DIF-3 remain to be elucidated. In this study, we...

  • Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B. van de Kooij, B; Rooswinkel, R W; Kok, F; Herrebout, M; de Vries, E; Paauwe, M; Janssen, G M C; van Veelen, P A; Borst, J // Oncogene;11/28/2013, Vol. 32 Issue 48, p5439 

    Anti-apoptotic Bcl-2 family members can contribute to tumorigenesis and may convey resistance to anti-cancer regimens. Therefore, they are important targets for novel therapeutics, particularly Bcl-2 homology (BH)3 mimetics. Bcl-B (BCL-2-like protein-10) is a relatively understudied member of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics